

Diabetic Retinopathy: Market Research Report

<https://marketpublishers.com/r/D9C7C5711FCEN.html>

Date: June 2010

Pages: 325

Price: US\$ 3,950.00 (Single User License)

ID: D9C7C5711FCEN

Abstracts

This report analyzes the US Market for Diabetic Retinopathy in US\$ Million.

Annual estimates and forecasts are provided for the period 2011 through 2015.

The report profiles 40 companies including many key and niche players such as Allergan, Inc., AstraZeneca PLC., Eyetech, Inc., Fovea Pharmaceuticals SA, Genentech, Inc., Gene Signal, Isis Pharmaceuticals, Inc., Lpath, Inc., MacuSight, Inc., OM Pharma S.A, OPKO Health, Inc., Oxford BioMedica Plc., pSivida Corp., Quark Pharmaceuticals, Inc., Sanwa Kagaku Kenkyusho Co., Ltd., Sirnaomics, Inc., Suzuken Co., Ltd., and Vitreoretinal Technologies, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

II. A US MARKET REPORT

1. MARKET OUTLOOK

Incidence and Prevalence of Diabetic Retinopathy Continue to Rise

Table 1. Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart)

Table 2. Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)

Table 3. Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)

Prevalence of Diabetes on the Rise

Huge Unmet Needs Fuel Demand for Pharmacological Drugs

Market Awaits First Approved Drug; Off-label Use Continues

Diabetic Retinopathy Drug Market to Post Dramatic Growth

Insulin – A Potential Therapy for Diabetic Retinopathy

Additional Trials Delay Arxxant's Launch

Lucentis Shows Promise in Diabetic Retinopathy Treatment

Avastin and Lucentis to Compete on Price

Pycnogenol Continues to Appeal to Researchers

Robo4 Protein – A Potential Therapeutic for Diabetic Retinopathy

Bevacizumab Bodes Potential As An Adjunct to Surgery PDR Treatment

2. DIABETIC RETINOPATHY DRUG CLASS – AN OVERVIEW

Drug Classes in Diabetic Retinopathy

VEGF Inhibitors

Pegaptanib

Bevacizumab

Ranibizumab

PKC Inhibitors

Corticosteroids

Aldose Reductase - AGE Inhibitors

Somatostatin Analog

Other Pharmacological Therapeutic Agents

3.PIPELINE OVERVIEW

Select Pipeline Drugs in Diabetic Retinopathy Market

An Overview of Select Pipeline Drugs

Arxxant (Eli Lilly)

Iluvien® (pSivida Corp.)

Atacand (AstraZeneca)

Lucentis (Genentech and Novartis)

Avastin (Genentech/Roche)

Vitreosolve® (Vitreo Retinal Technologies)

Posurdex (Allergan)

Macugen (EyeTech)

Cand5 (Opko Health, Inc.)

PF-4523655 (Quark Pharmaceuticals/Pfizer)

Intravitreal Triamcinolone Acetonide (Allergan)

Peribulbar Triamcinolone Acetonide (Bristol Myers)

Microplasmin (ThromboGenics N.V.)

Aflibercept (Regeneron/Bayer)

Sirolimus (MacuSight/Santen)

iCo-007 (iCo Therapeutics)

Other Drugs with Potential Benefits in DR Treatment

4.DISEASE OVERVIEW

Diabetes

Quick Facts on Diabetes

Diabetic Retinopathy

Leading Cause of Blindness in Diabetic Population
Pathogenesis of Diabetic Retinopathy
Clinical Features
Proliferative and Non-Proliferative Diabetic Retinopathy
Diabetic Macular Edema
Risk Factors for the Condition
Symptoms
Prevention of Diabetic Retinopathy
Detection of Proliferative Retinopathy and Macular Edema
Visual Acuity Test
Fundus Fluorescein Angiography
Ophthalmoscopy
Optical Coherence Tomography
Non-Mydriatic Fundus Photography
Dynamics of Evaluating Technologies
Frequency of Examinations
Treatment for Diabetic Retinopathy
Laser Surgery
Scatter Laser Treatment/ Panretinal Photocoagulation
Focal Laser Treatment/ Photocoagulation
Vitrectomy
Kenalog/ Triamcinolone Actinonide

5.RECENT INDUSTRY ACTIVITY

Sanofi-Aventis to Take Over Fovea Pharmaceuticals
New Injectable Steroid In-Line from Wakamoto Pharmaceutical
Sirion Therapeutics and Advanced Vision Research Signs Agreement
ActiveSite Develops Protease Inhibitor for Treating Diabetic Retinopathy
Pipex Acquires Global License for Additional Usage of Oral Flupirtine
MacuSight and Santen Ink License Agreement
OptiMedica Enters into Distribution Agreement with Topcon Medical
Lpath Submits IND for iSONEP™
Iris Pharma Merges with Clirophtha
Isis Receives Milestone Payment for Initiating Trials of iCo-007
Eli Lilly Withdraws Marketing Authorization Application for Arxxant in Europe
ThromboGenics Begins Phase IIb Trial of Microplasmin in the US

6.FOCUS ON SELECT GLOBAL PARTICIPANTS

Allergan, Inc. (US)
AstraZeneca PLC (UK)
Eyetechn, Inc. (US)
Fovea Pharmaceuticals SA (France)
Genentech, Inc. (US)
Gene Signal (Switzerland)
Isis Pharmaceuticals, Inc. (US)
Lpath, Inc. (US)
MacuSight, Inc. (US)
OM PHARMA S.A (Switzerland)
OPKO Health, Inc. (US)
Oxford BioMedica Plc. (UK)
pSivida Corp. (US)
Quark Pharmaceuticals, Inc. (US)
Sanwa Kagaku Kenkyusho Co., Ltd. (Japan)
Sirnaomics, Inc. (US)
Suzuken Co., Ltd. (Japan)
Vitreoretinal Technologies, Inc. (US)

7.US MARKET FORECASTS

Table 4. US Diabetic Retinopathy Drugs Market Potential: Annual Sales Forecasts in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 40 (including Divisions/Subsidiaries - 43)

Region/CountryPlayers

The United States

Canada

Japan

Europe

France

Germany

The United Kingdom

Rest of Europe

I would like to order

Product name: Diabetic Retinopathy: Market Research Report

Product link: <https://marketpublishers.com/r/D9C7C5711FCEN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D9C7C5711FCEN.html>